Six big things in metastatic prostate... - Fight Prostate Ca...

Fight Prostate Cancer

2,900 members1,134 posts

Six big things in metastatic prostate cancer

marnieg46 profile image
7 Replies

Those members of the Fight Prostate Cancer hub of the HU site, who follow or intend to follow, the general standard of care currently in place in America and Australia might find Declan Murphy’s recent podcast of interest.  

Declan, from the Peter MacCallum Cancer Centre in Melbourne, has published extensively especially in the area of prostate cancer and is an internationally recognised key opinion leader in all aspects of PC. 

This podcast is centered around interviewing two GU oncology experts who recently visited Australia to do a lecture tour on hot topics in metastatic prostate cancer.  

Dr Tian Zhang from Southwestern in Dallas, and Dr Rahul Aggarwal from UCSF were asked by Declan to highlight and discuss three key areas in each of metastatic hormone sensitive prostate cancer and metastatic castrate resistant prostate cancer to help unpick the stream of data in these fast-moving areas.   

To quote Declan – ‘What areas did they chose to highlight?? Well have a listen!’ 

Note:  this podcast does not explore alternative treatment or non-treatment options that some may choose to follow but does outline the standard of care approach offered in many countries.

   youtu.be/ohSvuveq_-0

Written by
marnieg46 profile image
marnieg46
To view profiles and participate in discussions please or .
Read more about...
7 Replies
cujoe profile image
cujoe

Ms M - Excellent presentation moderated by your friends and Ron's doc at PM. Delcan and Dr. Eapsen are the sort of docs that would make one want to the be treated at PeterMac. Too long a commute for most of us in the US, but perfect for Ron and for your new contributing role there.

The notion of PSMA scans 'correctly staging" PCa vs "restaging" is a very useful distinction and shows the value of PSMA use earlier in the diagnosis of disease state.

The discussion at the end about patient selection in clinical trials points out the problem for outliers - that they may be deprived of access to potential drugs with narrow efficacy profiles, because the drugs are never approved. (Due to that narrow efficacy - i.e.; only "blockbuster" drugs get approved and make it to market.)

It seems to reflect Siddhartha Mukherjee's Second Rule in his The Laws of Medicine: " 'Normals' teach us rules; 'outliers' teach us laws." . . . He goes on the say, "Every outlier represents an opportunity to refine our understanding of disease . . .rather than spending an enormous effort trying to figure out why a drug had commonly failed . . . try to understand why it had occasionally succeeded."

This is obviously an issue that Delcan is passionate about. He may well be an medical practitioner "outlier" himself.

Thanks for the link. All good info for PCa patients to take the time to review.

Ciao - K9

marnieg46 profile image
marnieg46 in reply tocujoe

Yes to all the points you raise cujoe.

We've been very fortunate in having access to Declan at important points along the journey. He's always very generous with his time even though he's not Ron's MO. In person he's just like he presents in the video. I thought you'd like the 'resstaging' distinction.

NPfisherman profile image
NPfisherman

Marnie,

I will add to K9 Terror's statements. A great video... some of their talking points mirrored my own thoughts and statements... They see Docetaxel being pushed back to a later state, and the standard being ARPI and ADT on diagnosis.... This makes total sense based on the CHECKMATE 650 trial results.. As I said to George71, the future of cancer therapy is immunotherapy... not taxane /chemotherapy...

They also talked about too many patients being started on ADT only and how that was leading to resistance... and let's not forget death...

Thanks for posting this interesting video with Peter Mac's Declan Murphy... a renown MD in Urology/Oncology and Ron's MO...

Dave

marnieg46 profile image
marnieg46 in reply toNPfisherman

Thanks Dave. Glad you found it of interest.

I often think back to 2019 when Ron first became metastatic with multiple mets and he was sent to a different hospital to be considered for a trial. Although he didn't qualify for the trial, in the report back to his urologist, the MO suggested he would benefit from double therapy. I often think back and wonder if his urologist had taken up the suggestion Ron might of had longer duration before becoming castrate resistant. Not sure if it was Renu or Declan who commented that once a person develops mets they should be referred by his urologist to a MO.

d3is4me profile image
d3is4me

Marnie Thank you very much for this video. It is the most informative discussion I have seen since being DX, gives me 100% confidence in my decisions on doctors and treatments.

Ross

marnieg46 profile image
marnieg46

That's great Ross you found it helpful Yes I agree. Very comprehensive.

Coincidental but just a few minutes ago Ron asked how you were going but I hadn't checked with you in a while. Hope all still goes well.

MateoBeach profile image
MateoBeach

thanks Marnie. Very interesting discussion and valuable perspectives. Big hugs to you and Ron.

Not what you're looking for?

You may also like...

Consider Genetic Testing in All Metastatic Prostate Cancers— Expert panel recommendations from MedPage Today - June 10, 2020

At last some definitive support for genetic testing for PCa patients. From the MedPage Today...
cujoe profile image

Metastatic prostate cancer due to have chemotherapy

Hi everyone, My father is due to have chemotherapy for advanced metastatic prostate cancer . He is...
Panthava profile image

BLUE SKY NEWS - AUGUST 2022

While some of the content of the August edition of the Blue Sky New’s publication from...
marnieg46 profile image

FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer

From several day ago. A new treatment tool for mCRPC patients with BRCA mutations. From the FDA:...
cujoe profile image

Study Solves Testosterone’s Paradoxical Effects in Prostate Cancer, Duke Health, Published September 04, 2024

This research appears to be a major breakthrough in our understanding of PCa's development and...
cujoe profile image